An analysis cited in HealthExec of the Walgreens buy from the SEC 8-K filing indicates that Sycamore Partners’ offer is a near-classic leveraged buyout, with Sycamore taking on much more debt than ...
The original $0.41 cash for current outstanding shares not owned by Ms. Wojcicki (or not rolled over by current shareholders) Plus three contingent value rights (CVRs) representing the potential ...